Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
BEA-17
product2 mentionslast seen Sep 22, 2026
First-in-class oral LSD1-CoREST degrader being developed as a precision immunotherapy for glioblastoma.
Relationships 5
- BEA-17applies toglioblastoma treatment99% confidence2 sources
- U.S. Food and Drug AdministrationapprovesBEA-1799% confidence2 sources
- Beactica TherapeuticsdevelopsBEA-1799% confidence2 sources
- BEA-17composed ofLSD1-CoREST degradation93% confidence1 source
- BEA-17depends onLSD1-CoREST degrader90% confidence1 source
Relationship
BEA-17applies toglioblastoma treatment
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- newsPR NewswireSep 22, 2026Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma
being developed as a precision immunotherapy for glioblastoma (GBM)
- newsPR NewswireSep 22, 2026Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma
being developed as a precision immunotherapy for glioblastoma (GBM)